Table 4.
Age- and multivariable-adjusted OR (95% CI) for associations between baseline level of IGFBP-2 and risk of atypical hyperplasia of the breast after stratification by hormone therapy (HT) use.
| IGFBP-2 (µIU/mL) | Co/Ca | Model 1 ORa | Model 2 ORb | Co/Ca | Model 3 ORc |
|---|---|---|---|---|---|
| Nonusers of HT | |||||
| Q1 | 28/38 | 1.0Ref. | 1.0Ref. | 25/35 | 1.0Ref. |
| Q2 | 42/25 | 0.44 (0.21–0.95) | 0.47 (0.20–1.08) | 38/22 | 0.48 (0.20–1.15) |
| Q3 | 43/45 | 0.65 (0.32–1.33) | 0.72 (0.33–1.60) | 40/41 | 0.66 (0.29–1.52) |
| Q4 | 47/31 | 0.40 (0.19–0.83) | 0.38 (0.15–0.93) | 47/30 | 0.33 (0.13–0.86) |
| Trend | 0.06 | 0.11 | 0.06 | ||
| Unopposed estrogen users | |||||
| Q1 | 24/20 | 1.0Ref. | 1.0Ref. | 22/19 | 1.0Ref. |
| Q2 | 11/19 | 2.16 (0.78–5.99) | 2.51 (0.87–7.23) | 8/17 | 2.42 (0.81–7.21) |
| Q3 | 12/12 | 1.11 (0.38–3.24) | 1.27 (0.42–3.89) | 12/12 | 1.12 (0.36–2.49) |
| Q4 | 12/11 | 0.67 (0.21–2.15) | 1.54 (0.42–5.62) | 12/11 | 1.37 (0.37–5.06) |
| Trend | 0.28 | 0.79 | 0.94 | ||
| Estrogen plus progestin users | |||||
| Q1 | 17/19 | 1.0Ref. | 1.0Ref. | 16/17 | 1.0Ref. |
| Q2 | 16/25 | 1.60 (0.64–3.98) | 2.06 (0.79–5.38) | 15/25 | 2.00 (0.76–5.25) |
| Q3 | 14/21 | 1.26 (0.45–3.52) | 1.43 (0.48–4.28) | 14/21 | 1.41 (0.47–4.24) |
| Q4 | 9/9 | 1.00 (0.30–3.31) | 1.37 (0.38–5.00) | 9/9 | 1.29 (0.35–4.75) |
| Trend | 0.70 | 0.91 | 0.85 |
aModel 1 adjusted for age and BMI (<25, 25–<30, 30–<35, ≥35 kg/m2).
bModel 2 additionally adjusted for serologic level of insulin, adiponectin, C-reactive protein, and tertile of estradiol.
cModel 3 additionally adjusted for serologic level of insulin, adiponectin, C-reactive protein, and tertile of estradiol and restricted to those without a history of diabetes.